• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NEJM - Zika Virus Infection in Pregnant Women in Rio de Janeiro - December 13, 2016 - Substantial percentage of adverse outcomes in fetuses and infan

sharon sanders

Editor-in-Chief & President
Zika Virus Infection in Pregnant Women in Rio de Janeiro

Patr?cia Brasil, M.D., Ph.D., Jos? P. Pereira, Jr., M.D., M. Elisabeth Moreira, M.D., Ph.D., Rita M. Ribeiro Nogueira, M.D., Ph.D., Luana Damasceno, Pharm.D., Mayumi Wakimoto, M.D., Ph.D., Renata S. Rabello, D.V.M., Ph.D., Stephanie G. Valderramos, M.D., Ph.D., Umme-Aiman Halai, M.D., Tania S. Salles, M.D., Ph.D., Andrea A. Zin, M.D., Ph.D., Dafne Horovitz, M.D., Ph.D., Pedro Daltro, M.D., Ph.D., Marcia Boechat, M.D., Ph.D., Claudia Raja Gabaglia, M.D., Ph.D., Patr?cia Carvalho de Sequeira, Ph.D., Jos? H. Pilotto, M.D., Ph.D., Raquel Medialdea-Carrera, Ph.D., Denise Cotrim da Cunha, M.D., Liege M. Abreu de Carvalho, M.D., Marcos Pone, M.D., Andr? Machado Siqueira, M.D., Ph.D., Guilherme A. Calvet, M.D., Ph.D., Ana E. Rodrigues Bai?o, M.D., Elizabeth S. Neves, M.D., Ph.D., Paulo R. Nassar de Carvalho, M.D., Renata H. Hasue, Ph.D., Peter B. Marschik, Ph.D., Christa Einspieler, Ph.D., Carla Janzen, M.D., Ph.D., James D. Cherry, M.D., Ana M. Bispo de Filippis, Ph.D., and Karin Nielsen-Saines, M.D.

December 13, 2016DOI: 10.1056/NEJMoa1602412

snip

RESULTS

A total of 345 women were enrolled from September 2015 through May 2016; of these, 182 women (53%) tested positive for ZIKV in blood, urine, or both. The timing of acute ZIKV infection ranged from 6 to 39 weeks of gestation. Predominant maternal clinical features included a pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 27% had fever (short-term and low-grade). By July 2016, a total of 134 ZIKV-affected pregnancies and 73 ZIKV-unaffected pregnancies had reached completion, with outcomes known for 125 ZIKV-affected and 61 ZIKV-unaffected pregnancies. Infection with chikungunya virus was identified in 42% of women without ZIKV infection versus 3% of women with ZIKV infection (P<0.001). Rates of fetal death were 7% in both groups; overall adverse outcomes were 46% among offspring of ZIKV-positive women versus 11.5% among offspring of ZIKV-negative women (P<0.001).

Among 117 live infants born to 116 ZIKV-positive women, 42% were found to have grossly abnormal clinical or brain imaging findings or both, including 4 infants with microcephaly.

Adverse outcomes were noted regardless of the trimester during which the women were infected with ZIKV (55% of pregnancies had adverse outcomes after maternal infection in the first trimester, 52% after infection in the second trimester, and 29% after infection in the third trimester).



http://www.nejm.org/doi/full/10.1056...=featured_home
 
Last edited by a moderator:
Back
Top